target upgrad unit state go sg websit
stronger expect refocus human medicin anim health ipo
upsid tp
nc chang
compani solid result driven pharma cost contain
manufactur market led compani rais fy guidanc
anim health ipo schedul increas tp
reiter hold rate market expect valuat
alreadi high
strong pharma cost control group sale grew constant
exchang rate consensu estim thank robust
perform certain cancer endocrinolog product trulic diabet
weekli direct competitor novo victoza beat consensu
estim market share gain market expans humalog human insulin
consensu trulic gain market share still fast grow
market basaglar biosimilar version sanofi lantu line
expect thank broader us access market share rose end-
confirm meaning price pressur us sale
recent launch taltz direct competitor novarti cosentyx psoriasi slightli
higher consensu acceler prescript weaker due rebat
adjust impact support view market expand drug
strong perform anim health busi group sale remain
pressur cer divis sale came consensu
expect compani announc ipo divis surpris
synergi pharma ev elanco anim health
sotp total group ev adjust ep reach consensu
thank higher gross margin manufactur effici lower market cost
sale
compani rais sale ep guidanc thank better
expect sale perform favour currenc effect cost guid
group sale vs non-gaap ep
vs lift estim reflect stronger expect
result notabl diabet cancer reflect new buy-back programm
tp increas vs thank higher estim peer multipl
recent sector out-performance premium larg pharma premium vs
lt margin vs hold reiter consensu pipelin expect high
earn growth seen line sector due patent expiri ahead
valuat attract premium price-to-earnings vs pharma sector
societ general sg seek busi compani cover research report result investor awar
sg may conflict interest could affect object report investor consid report singl factor
make invest decis pleas appendix end report analyst certif
simplifi main product
sg cross asset research/equ compani data streetacount consensu
confer call feedback manag tone pipelin product perform
posit overal market expect alreadi high
compani reiter despit elanco ipo anim health ev sotp
continu look potenti acquisit compani product strengthen
portfolio five core therapeut area
sever question call impact impli blueprint
presid trump us healthcar reform manag emphasis view us
author multipl way reduc increas net drug price innov
continu reward
despit recent setback compani continu commit alzheim two
product phase ii combin monotherapi data due limit market
lot question late-stag portfolio notabl product differenti
migrain first class importantli opportun offer
tanezumab altern opioid pain especi light opioid crisi safeti
key latter trial address on-going read-out expect
tradjenta weekli diabet direct competitor novo ozemp underli
growth remain strong contrari jardianc dpp-iv oral drug diabet soft
sequenti perform explain adjust inventori rebat
trulic us total prescript market growth
basaglar us total prescript market growth
overal manag tone call rather upbeat think market
expect pipelin alreadi high valuat attract premium vs
pharma peer earn growth seen line compani
expos patent expir sale
jardianc famili us total prescript market growth
compani increas sale ep guidanc thank better
expect sale perform favour currenc effect cost guidanc call
group sale vs non-gaap ep vs
label updat io combo keytruda keynot
valuat tp increas vs
increas estim reflect stronger result notabl diabet
cancer reflect new buy-back programm rais tp
higher estim peer multipl recent sector out-performance premium larg pharma
premium vs lt margin vs
share basic year end/outstand
share price average hist yr current
valu minor
valu financi invest
depreci amortis
chang work capit
flow oper activ
flow invest activ
flow financ activ
net chang cash result cf
intang
report complet jul cet
merck co inc us buy
follow name research analyst herebi certifi certifi view express research report accur reflect
person view subject secur issuer ii part compens
relat directli indirectli specif recommend view express report florent cesped
analyst author research employ sg affili locat includ limit pari london new york
hong kong tokyo bangalor frankfurt madrid milan geneva seoul warsaw moscow
tp deriv sotp dcf order captur short-term perform lt opportun pipelin
sotp averag valuat base larg pharma ev/ebita multipl premium pharma divis line
anim health dcf lt growth long-term ebita margin wacc
downsid stronger competit recent launch product cancer immune-inflamm low- mid-singl digit
ebit margin target miss low mid-singl digit impact ebit
upsid better penetr talz psoriasi high-single-digit upsid ebit
sg equiti research rate month period
equiti rate dispers relationship
buy absolut total sharehold return forecast
month period
hold absolut total sharehold return forecast
month period
sell absolut total sharehold return forecast
plu forecast cash dividend incom includ incom
special dividend paid month period rate
determin rang describ time
initi coverag chang rate subject limit
manag discret time rate may fall outsid
rang market price movement and/or
short term volatil trade pattern interim deviat
specifi rang permit becom subject
review research manag
sector weight definit month period
sector weight assign sg equiti research
strategist distinct separ sg equiti research
analyst rate base relev
overweight sector expect outperform relev broad
market benchmark next month
neutral sector expect perform in-lin relev
broad market benchmark next month
underweight sector expect under-perform relev
broad market benchmark next month
prefer least prefer stock select
cover analyst base individu analyst coverag
univers sg equiti research strategist
price inform includ report market close unless otherwis state
disclaim sourc inform exclus properti morgan stanley capit intern inc without
prior written permiss inform intellectu properti may reproduc redissemin
use creat financi product includ indic inform provid basi user assum entir
risk use made inform affili third parti involv relat comput compil
inform herebi expressli disclaim warranti origin accuraci complet merchant fit particular
purpos respect inform without limit forego event shall affili
third parti involv relat comput compil inform liabil damag kind morgan
stanley capit intern index servic mark affili similar languag may
provid approv advanc
sg act co-manag novarti financ sa bond issu senior
sg act global co-ordin sanofi multi-tranch senior bond issu eur yr yr yr yr yr yr
